India`s drug major Ranbaxy Laboratories used "fraudulent" data to get USFDA nod to sell its generic drugs, according to whistleblower Dinesh Thakur, who has also accused the drug-maker of faking test results.
An Indian origin whistle-blower, who exposed a massive fraud by the Indian pharmaceutical giant Ranbaxy, has accused the generic drug maker of faking test results for approval by the US drug regulator.
Ranbaxy Laboratories "systemically violated" good manufacturing practices, says the whisteblower whose alert led to a US probe, a day after India`s top drugmaker agreed to pay a hefty USD 500 million to settle charges over its adulterated drugs.
The US arm of Indian drug major Ranbaxy Laboratories has entered into an in-licensing agreement with Alembic Pharmaceuticals Limited to exclusively market the generic version of Pfizer Inc.`s anti-depression drug Pristiq in the US.
On the occasion of World Malaria Day on Wednesday, India has a good news for the world. The country has developed an indigenous new malaria drug which in turn will boost India’s pharmaceutical research.
The country`s largest drug maker by sales, Ranbaxy Laboratories, today said it would launch Olmesartan Medoxomil, an anti-hypertensive drug from parent company Daiichi Sankyo`s portfolio, in six African countries.